早期胰周肠系膜脂肪变化超越减重预测MASLD肝脏改善的持久性
研究纳入631例初治MASLD患者,随访96周,用MRI量化腹部脂肪库。48周时胰周肠系膜脂肪厚度(MFT1)相对下降越多,96周时MRI-PDFF和LSM应答丢失风险越低,独立于其他脂肪库。MFT1早期变化可能预测肝脏应答持久性。
要点
- 48周MFT1相对下降每10%,96周MRI-PDFF应答丢失风险降低(OR 0.48)。
- MFT1变化对MRI-PDFF和LSM应答丢失有判别能力(AUC 0.70和0.77)。
- MFT2、PFT和PrFT变化未显示独立预测价值。
核心结论
- 早期MFT1变化与后续肝脏脂肪变和纤维化应答丢失相关,提示对MASLD肝脏应答持久性有潜在预后价值。
研究设计与样本
- 前瞻性队列研究,2015年1月至2024年3月连续纳入初治MASLD患者,随访96周。
- 共631例患者,平均年龄41.5±13.8岁,男性占72.0%。
- 用MRI量化肝脂肪含量、PFT、MFT1、MFT2和PrFT,2D-SWE测LSM,48和96周评估应答。
主要发现
- 48周MFT1相对下降每10%,96周MRI-PDFF应答丢失OR为0.48(95%CI 0.34–0.69,p<0.001)。
- 48周MFT1相对下降每10%,96周LSM应答丢失OR为0.53(95%CI 0.28–0.99,p=0.046)。
- MFT1相对变化判别MRI-PDFF和LSM应答丢失的AUC分别为0.70(95%CI 0.64–0.76)和0.77(95%CI 0.67–0.88)。
关键数值与推荐
- MFT1相对下降每10%对应MRI-PDFF应答丢失OR 0.48(95%CI 0.34–0.69,p<0.001)。
- MFT1相对下降每10%对应LSM应答丢失OR 0.53(95%CI 0.28–0.99,p=0.046)。
- MFT1变化判别MRI-PDFF应答丢失AUC 0.70(95%CI 0.64–0.76),判别LSM应答丢失AUC 0.77(95%CI 0.67–0.88)。
临床怎么用
- 对MASLD生活方式干预患者,可关注48周时MFT1相对变化以辅助判断肝脏应答持久性。
- MFT1早期下降幅度较大者,96周肝脏脂肪变和纤维化应答丢失风险可能更低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aims Various visceral adipose tissue depots exhibit heterogeneous metabolic properties. This study aims to explore whether specific abdominal fat compartments differentially predict loss of sustained treatment response to lifestyle interventions in metabolic dysfunction-associated steatotic liver disease (MASLD). Materials and Methods Consecutive treatment-naïve MASLD patients were prospectively enrolled from January 2015 to March 2024, with a 96-week follow-up period. Liver fat content, preperitoneal fat thickness (PFT), peripancreatic mesenteric fat thickness (MFT1), periumbilical mesenteric fat thickness (MFT2) and perirenal fat thickness (PrFT) were quantified using magnetic resonance imaging. Liver stiffness measurement (LSM) was assessed by 2D-SWE. Treatment responses were evaluated at 48 and 96 weeks, and the primary outcome was loss of response at 96 weeks. Results A total of 631 MASLD patients (mean age: 41.5 ± 13.8 years; 72.0% male) were included. Logistic regression analyses revealed that a greater 48-week relative decrease in MFT1 (per 10% relative reduction), rather than in MFT2, PFT or PrFT, was independently associated with lower odds of losing MRI-PDFF response (OR: 0.48, 95% CI: 0.34–0.69, p < 0.001) and LSM response (OR: 0.53, 95% CI: 0.28–0.99, p = 0.046) at 96 weeks. Receiver operating characteristic curve analyses indicated that relative changes in MFT1 showed discriminatory ability for the loss of MRI-PDFF and LSM responses, with areas under the curves of 0.70 (95% CI: 0.64–0.76) and 0.77 (95% CI: 0.67–0.88), respectively. Conclusions Early changes in MFT1 were associated with subsequent loss of response in hepatic steatosis and fibrosis, suggesting potential prognostic value for hepatic response durability in MASLD.
引用
- Diabetes, Obesity and Metabolism:Early Changes in Peripancreatic Mesenteric Fat Beyond Weight Loss Predict Durability of Hepatic Improvements in MASLD
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。